These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1659206)

  • 1. HMG CoA reductase inhibitors affect Na(+)-H+ antiport activity in human lymphoblasts.
    Ng LL; Davies JE
    Am J Physiol; 1991 Nov; 261(5 Pt 1):C780-6. PubMed ID: 1659206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin and intracellular pH regulation by the Na+/H+ antiport of SV40-virus-transformed human MRC5 fibroblasts.
    Davies JE; Ng LL
    Clin Sci (Lond); 1993 Jun; 84(6):633-43. PubMed ID: 8392920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
    Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
    Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis in Syrian hamster C100 cells by mevinolin, 25-hydroxycholesterol, and mevalonate: the role of posttranscriptional control.
    Peffley DM
    Somat Cell Mol Genet; 1992 Jan; 18(1):19-32. PubMed ID: 1546367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abolition of mevinolin-induced growth inhibition in human fibroblasts following transformation by simian virus 40.
    Larsson O; Barrios C; Latham C; Ruiz J; Zetterberg A; Zickert P; Wejde J
    Cancer Res; 1989 Oct; 49(20):5605-10. PubMed ID: 2551491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
    Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
    Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level.
    Peffley DM; Gayen AK
    Arch Biochem Biophys; 1997 Jan; 337(2):251-60. PubMed ID: 9016820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mevalonic acid as an initiator of cell growth. Studies using human lymphocytes and inhibitors of endogenous mevalonate biosynthesis.
    Yachnin S
    Oncodev Biol Med; 1982; 3(2-3):111-23. PubMed ID: 7122252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids and cellular Na+/H+ antiport activity in diabetic nephropathy.
    Ng LL; Davies JE
    Kidney Int; 1992 Apr; 41(4):872-6. PubMed ID: 1325009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate.
    Oms P; Assie N; Bruniquel F; Degryse AD; van Haverbeke G; Delhon A
    Pharmacol Toxicol; 1995 Dec; 77(6):391-6. PubMed ID: 8835365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement for mevalonate in cycling cells: quantitative and temporal aspects.
    Doyle JW; Kandutsch AA
    J Cell Physiol; 1988 Oct; 137(1):133-40. PubMed ID: 3170653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation.
    Chakrabarti R; Engleman EG
    J Biol Chem; 1991 Jul; 266(19):12216-22. PubMed ID: 1712015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mevalonate regulates polysome distribution and blocks translation-dependent suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA: relationship to translational control.
    Peffley DM; Gayen AK
    Somat Cell Mol Genet; 1995 May; 21(3):189-204. PubMed ID: 7482033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in the ability of compactin and oxidized cholesterol, both known inhibitors of cholesterol biosynthesis, to suppress in vitro immune responses.
    Humphries GM
    Cancer Res; 1981 Sep; 41(9 Pt 2):3789-91. PubMed ID: 7260948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.
    Tsuji A; Saheki A; Tamai I; Terasaki T
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1085-90. PubMed ID: 8263769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication.
    Soma MR; Corsini A; Paoletti R
    Toxicol Lett; 1992 Dec; 64-65 Spec No():1-15. PubMed ID: 1471162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.